ETFs Investing in Royalty Pharma Plc Class A Stocks
This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover a range of investment focuses, from diversified total market funds to sector-specific and ESG-focused options.
Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades
Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additional 461,953 shares held indirectly through SCH Investment Partners LLC.
[Form 4] Royalty Pharma plc Insider Trading Activity
Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Urist directly holds no Class A shares but maintains an indirect holding of 19,020 shares through an IRA.
Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M
Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted on May 8, 2026, as part of the company's equity compensation program. While the sales don't explicitly link to the award, the various transactions relate to Urist's holdings.
[144] Royalty Pharma plc SEC Filing
This article reports a Form 144 SEC filing by Royalty Pharma plc (RPRX), indicating a proposed sale of 100,000 Class A Ordinary Shares with an aggregate market value of $5,709,000. These shares were acquired from the issuer in a private transaction on February 14, 2025. The filing, accepted by the SEC on July 1, 2026, also details the securities exchange as NASDAQ.
Royalty Pharma (RPRX) director gets equity grant in lieu of cash
Royalty Pharma (RPRX) director Bonnie L. Bassler received an equity grant of 689 Class A Ordinary Shares as compensation, valued at $37,500, in lieu of a quarterly cash retainer. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan, with each share valued at $54.3998. Following this transaction, Bassler directly holds 79,181 Class A Ordinary Shares, highlighting a non-cash compensation method rather than an open-market purchase or sale.
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD
The article mentions the enterprise value to revenue forward for Royalty Pharma Plc Class A, traded on the Stuttgart Stock Exchange under the symbol RPD. It is a financial data point for the company in the Pharmaceuticals: Major industry within Health Technology. The content provided is minimal and appears to be a stub or a section of a larger financial information display, highlighting the period and value change.
Price to earnings forward of Royalty Pharma Plc Class A – SWB:RPD
This article provides access to the "Price to earnings forward" financial metric for Royalty Pharma Plc Class A (SWB:RPD) on TradingView. It indicates that the market for this stock was closed with no trades at the time of access. The primary content focuses on directing users to financial data for the company.
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan
An entity linked to Christopher Hite, EVP and Chairman, Partnering at Royalty Pharma plc, sold 150,000 Class A Ordinary Shares in open-market transactions on June 23, 2026. These sales, executed at weighted average prices around $54, were pre-planned under a Rule 10b5-1 trading plan adopted in March 2026. Following these transactions, Hite and the associated entity still retain a substantial holding of Royalty Pharma shares.
Form 4 Royalty Pharma Plc For: 25 June By Investing.com
This article provides details of a Form 4 filing for Royalty Pharma Plc on June 25, 2026. Form 4 filings typically report changes in beneficial ownership of securities by company insiders. The article also includes current market data for various indices, commodities, and currencies.
Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan
Royalty Pharma EVP Marshall Urist sold 9,098 Class A Ordinary Shares at a weighted average price of $55.1843 per share, totaling over $502,000, under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following this transaction, Urist directly holds 9,099 shares. The sale reinforces that such planned trades are not based on immediate insider information.
Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX)
This article provides an overview of Royalty Pharma plc (NASDAQ: RPRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings per share and revenue, and key metrics like market capitalization, EBITDA, and dividend yield, advising readers to conduct their own research.
Form 144 Royalty Pharma plc For: 24 June By Investing.com
This article from Investing.com is a brief report about Royalty Pharma plc's Form 144 filing for June 24. It includes the ticker symbol RPRX which showed a slight increase of 0.76%. The content consists mostly of market data, indices, commodity prices, and other financial performance indicators for various companies and markets.
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX)
Marshall Urist, an insider at Royalty Pharma plc (NASDAQ: RPRX), reported selling 13,684 shares on May 14, 2026, for $726,137.82 and another 13,684 shares on May 20, 2026, for $721,837.21. These transactions were disclosed in a Form 144 SEC filing, which also noted an Equity Performance Award of 9,098 shares granted on May 8, 2026. The filing provides details on the nature of these transactions and the associated financial figures.
[144] Royalty Pharma plc SEC Filing
Royalty Pharma plc (RPRX) has filed a Form 144 with the SEC, indicating a proposed sale of 30,000 Class A Ordinary Shares by an individual who acquired them through a purchase in an IPO's reserved shares program on June 18, 2020. The aggregate market value of these shares is $1,660,500, with the sale scheduled for June 23, 2026, on NASDAQ through Merrill Lynch. The filing confirms no material adverse information is known by the seller that has not been publicly disclosed.
[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed Amendment No. 8 to their Schedule 13D for Royalty Pharma plc, indicating their beneficial ownership has decreased to 4.8% of outstanding Class A shares, below the 5% threshold. This filing acts as a final "exit" amendment, relieving them of further Schedule 13D reporting obligations for Royalty Pharma. The report details the trust and fund structures through which the shares are held and disclaims beneficial ownership by associated individuals.
Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant
Royalty Pharma director Gregory Norden was awarded 4,545 Class A Ordinary Shares in restricted stock units (RSUs) on June 5, 2026, as an equity grant under the company’s 2020 Independent Director Equity Incentive Plan. The RSUs have a grant price of $0.00 per share and are set to vest 100% on the earlier of one year from the grant date or the next annual shareholders’ meeting. Following this transaction, Norden directly holds 196,348 Class A Ordinary Shares.
Royalty Pharma (RPRX) director receives 4,545 share unit award
Royalty Pharma plc director Elizabeth H. Weatherman was granted an equity award of 4,545 restricted stock units, which are Class A Ordinary Shares. This compensation-related award, at no cash cost, will vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this transaction, Weatherman directly holds 13,103 shares.
Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX)
Royalty Pharma director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). These RSUs, granted under the company's 2020 Independent Director Equity Incentive Plan, generally vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this grant, Love directly holds 58,393 Class A Ordinary Shares in Royalty Pharma (RPRX).
Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant
Royalty Pharma plc director David C. Hodgson received a grant of 4,545 restricted stock units (RSUs) tied to Class A ordinary shares as equity compensation. These RSUs, awarded under the company's 2020 Independent Director Equity Incentive Plan, will vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Hodgson holds these units solely for the benefit of General Atlantic Service Company, L.P., disclaiming personal beneficial ownership.
Royalty Pharma (RPRX) awards 4,545 RSUs to board director
Royalty Pharma (RPRX) reported that its director, Catherine M. Engelbert, received an award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). This award was granted under the company’s 2020 Independent Director Equity Incentive Plan at no cash cost to her. Following this transaction, Engelbert directly holds a total of 55,673 Class A Ordinary Shares, with the RSUs scheduled to vest on the earlier of one year from the grant date or the next annual shareholders' meeting.
Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan
Royalty Pharma plc (RPRX) director Vlad Coric was granted 4,545 Restricted Stock Units (RSUs) at no cost under the company's 2020 Independent Director Equity Incentive Plan. These RSUs will vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this award, Coric directly holds 15,343 Class A Ordinary Shares.
Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares
Royalty Pharma plc director Carole Ho was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units as compensation. The award, valued at $0.00 per share, is set to vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. Following this transaction, Ho directly holds 4,545 shares and indirectly holds 8,558 shares through a family trust.
Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares
Royalty Pharma (RPRX) director Bonnie L. Bassler was granted 4,545 restricted stock units (RSUs) as part of her compensation, increasing her direct holdings to 78,492 Class A Ordinary Shares. This award, made under the company's 2020 Independent Director Equity Incentive Plan, vests 100% on the earlier of one year from the grant date or the next annual shareholder meeting. The transaction is a routine, non-cash compensation grant rather than an open-market purchase or sale.
Cash from operating activities of Royalty Pharma Plc Class A – XETR:RPD
The article focuses on the "Cash from operating activities" for Royalty Pharma Plc Class A, traded on XETRA under the symbol RPD. It presents a data table showing the period, value, change, and percentage change for this financial metric. The content underscores the financial overview of Royalty Pharma Plc Class A on the TradingView platform.
Royalty Pharma (RPRX) shareholders back directors, pay and share issuance powers at 2026 AGM
Royalty Pharma plc shareholders approved all proposals at its 2026 Annual General Meeting, with a strong quorum of 88.08% voting power. Key approvals included the election of all nine director nominees, executive compensation on a non-binding basis, and the ratification and re-appointment of Ernst & Young as auditors. Shareholders also granted the board authority for potential share repurchases and for allotting shares, including without pre-emption rights, indicating broad support for the company's governance and financial flexibility.
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)
This article provides a comprehensive overview of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) stock, including its current price, performance metrics, and key statistics such as market cap, P/E ratio, and dividend yield. It also covers technical and fundamental analysis ratings from ChartMill, recent earnings reports, analyst forecasts, and company details, highlighting its business model of funding biopharmaceutical innovation through royalties.
Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale occurred near the stock's 52-week high, with the company showcasing strong Q1 2026 financial performance. Despite the sale, Coyne retains significant direct and indirect holdings in Royalty Pharma.
Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This transaction occurred as the stock traded near its 52-week high after a significant 69% return over the past year. While the shares held by the LLC involved in the sale are now zero, Coyne retains other indirect and direct holdings in the company.
Royalty Pharma (RPRX) CFO-linked entity sells 64,399 shares under 10b5-1 plan
Royalty Pharma's EVP & CFO, Terrance P. Coyne, through an affiliated entity (TPC RP EPA1 LLC), sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 24, 2026. While the selling entity now holds zero shares, Coyne maintains other direct and indirect holdings in the company.
Royalty Pharma EVP Marshall Urist sells $721,837 in shares By Investing.com
Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 13,684 Class A Ordinary Shares for $721,837 on May 20, 2026, as part of a prearranged trading plan. The sale occurred while RPRX stock was trading near its 52-week high, with the shares currently appearing overvalued according to InvestingPro analysis. Despite the sale, Urist retains significant direct and indirect holdings in the company.
Royalty Pharma (RPRX) EVP Urist sells 13,684 shares in 10b5-1 planned trade
Marshall Urist, EVP of Royalty Pharma (RPRX), sold 13,684 Class A Ordinary Shares on May 20, 2026, at a weighted average price of $52.7505 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Urist directly holds 18,197 shares and indirectly owns 19,020 shares through an IRA.
Royalty Pharma EVP Urist sells $726,137 in shares By Investing.com
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 13,684 Class A Ordinary Shares for over $726,000 on May 14, 2026, through a pre-arranged trading plan. Despite the sale, which occurred near the stock's 52-week high, Royalty Pharma shares are considered undervalued by InvestingPro analysis. The company recently reported strong Q1 2026 financial performance with double-digit growth in portfolio and royalty receipts.
Royalty Pharma EVP Urist sells $726,137 in shares
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 13,684 Class A Ordinary Shares for $726,137 on May 14, 2026. This transaction was part of a pre-arranged trading plan, and Urist still holds a significant amount of shares directly and indirectly. The sale occurs as Royalty Pharma shares are near their 52-week high, following strong Q1 2026 financial results.
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan
Marshall Urist, EVP of Research & Investments at Royalty Pharma (RPRX), sold 13,684 Class A Ordinary Shares on May 14, 2026, at a weighted average price of $53.0647 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. After the transaction, Urist directly holds 31,881 Class A shares and indirectly holds 19,020 shares through an IRA.
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden
Royalty Pharma director Gregory Norden executed a pre-arranged sale of 3,045 Class A Ordinary Shares at $53.00 per share on May 14, 2026, under a Rule 10b5-1 trading plan adopted in February 2026. Following this open-market transaction, Norden retains direct ownership of 191,803 Class A Ordinary Shares. The filing indicates a moderate impact and negative sentiment, typical for such pre-planned insider sales.
Royalty Pharma (Nasdaq:RPRX) - Stock Analysis
Royalty Pharma (RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. The company recently reported strong Q1 2026 results with double-digit royalty growth, significant capital deployment into new deals, and a raised dividend. While analysts anticipate strong future growth, some risks include a high debt level and the dividend not being fully covered by free cash flows.
Royalty Pharma EVP Urist sells $726,137 in shares
Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc, sold 13,684 Class A Ordinary Shares for a total of $726,137 on May 14, 2026. The sale was executed via a pre-arranged 10b5-1 trading plan. Despite the insider sale, Royalty Pharma's shares are trading near their 52-week high, and the stock is considered undervalued according to InvestingPro analysis, with strong financial performance reported for Q1 2026.
Royalty Pharma (NASDAQ: RPRX) Rule 144 notice for 13,684-share resale
Royalty Pharma plc (NASDAQ: RPRX) has filed a Rule 144 notice for the proposed resale of 13,684 shares of its Common Stock. The filing details an Equity Performance Award dated February 11, 2026, and a reported sale of 13,684 shares by Marshall Urist on May 14, 2026. This institutional disclosure is standard procedure for the resale of restricted securities and provides insights into insider transactions.
Royalty Pharma (RPRX) EVP gets 18,197-share equity award
Royalty Pharma plc's EVP of Research & Investments, Marshall Urist, was granted 18,197 Class A Ordinary Shares as an exempt acquisition related to the settlement of Equity Performance Awards. This transaction increased his direct holdings to 45,565 shares, with an additional 19,020 shares held indirectly through an IRA. The equity award was provided at no cash cost, aligning with Rule 16b-3 regulations for insider compensation.
[Form 4] Royalty Pharma plc Insider Trading Activity
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported an exempt acquisition of 24,263 Class A Ordinary Shares on May 6, 2026, received at no cost through an affiliated entity (TPC RP EPA1 LLC) as part of Equity Performance Awards. Following this transaction, TPC RP EPA1 LLC indirectly holds 64,399 Class A Ordinary Shares. The filing details Coyne's total direct and indirect holdings, including shares held by his spouse and IRA, and additional limited partnership interests and Class E shares that are exchangeable into Class A Ordinary Shares.
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma reported strong first-quarter results with 10% growth in portfolio receipts and a 21% increase in adjusted EBITDA. The company also announced significant capital deployment of $528 million. This performance led management to raise their revenue guidance and prompted an increase in the fair value estimate by Morningstar analysts.
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma
Morningstar has increased its fair value estimate for Royalty Pharma due to an improved growth outlook. The company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation, benefits from diverse royalty streams across various therapeutic areas, setting it apart from typical biotech firms. This positive outlook is supported by strong cash flows and new deals.
Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary
Royalty Pharma plc reported strong first-quarter 2026 financial results with revenue of $630.58 million and diluted EPS of $0.67, both showing significant increases compared to the prior-year quarter. This growth was driven by new royalty acquisitions, robust portfolio receipts from existing products, and strategic investments in new assets. The company also highlighted favorable regulatory and clinical catalysts that are expected to positively impact future cash flows.
Royalty Pharma commits up to $1.25B to new deals, lifts 2026 outlook
Royalty Pharma (RPRX) reported strong Q1 2026 results, with portfolio receipts increasing 10% to $925 million and royalty receipts up 13% to $887 million. The company announced commitments of up to $1.25 billion for new transactions and raised its full-year 2026 guidance for portfolio receipts to a range of $3.325 billion to $3.450 billion. This positive outlook is supported by increased R&D co-funding agreements and favorable clinical and regulatory updates across its portfolio.
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX)
Royalty Pharma recently announced a Q2 2026 dividend of US$0.235 per Class A ordinary share, reinforcing its focus on cash returns. The company's investment narrative is centered on reinvestment, buybacks, and royalty growth, supported by its 2026 portfolio receipts guidance of US$3,275 million to US$3,425 million. However, investors are urged to consider potential risks such as drug pricing reforms, patent pressure, and concentration risks that could impact future royalty streams.
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 34,791 Class A Ordinary Shares totaling approximately $1.73 million on April 28, 2026, through a pre-arranged 10b5-1 trading plan. These sales occurred as RPRX traded near its 52-week high after a strong 56% return over the past year. The company recently announced a quarterly dividend, partnered with Johnson & Johnson for R&D, received increased price targets from analysts, and appointed a Head of Artificial Intelligence, reflecting strategic growth and innovation.
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX)
Royalty Pharma recently declared a Q2 2026 dividend of US$0.235 per share, reinforcing its focus on cash returns alongside increased analyst optimism for upcoming earnings. This dividend, combined with positive 2026 portfolio receipts guidance, aims to signal management's confidence in funding buybacks and royalty acquisitions. However, the article suggests that investors should consider potential risks from drug pricing reforms and patent pressures despite the steady dividend.
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares totaling approximately $1.73 million on April 28, 2026, executed via a pre-arranged 10b5-1 trading plan. The sales occurred while RPRX was near its 52-week high, and InvestingPro analysis suggests the stock might be overvalued. Despite the sale, Coyne retains substantial indirect and direct holdings, and the company recently announced a dividend, a major R&D agreement with Johnson & Johnson, and positive analyst revisions, alongside appointing a Head of AI.
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 34,791 Class A Ordinary Shares worth approximately $1.73 million on April 28, 2026. These transactions, executed via a 10b5-1 trading plan, occurred while RPRX was near its 52-week high and is considered overvalued by InvestingPro. Despite this insider sale, the company recently announced a dividend, a major R&D agreement with Johnson & Johnson, received raised price targets from analysts, and appointed a Head of AI, indicating strategic growth.
